-
13m 52sPart 3 | Session 6 ACC 2026 with Dr Mehran: Leadership, Vision, and the Future of the College
-
5m 17sPart 3 | Session 7 Heart Failure in 2026: Practical Therapy Lessons From ACC.26
-
6m 14sPart 3 | Session 8 RECOVER-Autonomic - Ivabradine for Post-COVID POTS
-
9m 23sPart 3 | Session 9 ORBITA-CTO - PCI Versus Placebo for Chronic Total Occlusion in Stable Angina
-
7m 21sPart 3 | Session 10 CHIP-BCIS3 – Percutaneous LV Unloading in High-Risk PCI
-
16m 1sPart 3 | Session 11 Dr Reddy & Dr Nair on CHAMPION-AF: Redefining Stroke Prevention
-
7m 26sPart 3 | Session 12 FAST III - FFR vs vFFR to Guide Revascularisation
-
5m 34sPart 3 | Session 13 AI-Based Retinal Imaging for Atherosclerotic Cardiovascular Risk
-
4m 5sPart 3 | Session 14 CORALreef — Durability of Enlicitide for Lipid Lowering in Hypercholesterolaemia
-
5m 18sPart 4 | Session 1 STEMI-DTU, GOFRESH, and HI-PEITHO
-
3m 7sPart 4 | Session 2 SURPASS CVOT, HI-PEITHO, SURVIV
-
5m 8sPart 4 | Session 3 Top Takeaways from the 2026 Dyslipidaemia Guidelines
-
2m 21sPart 4 | Session 4 3 ACC.26 Highlights for the Cardiology Pharmacist
-
10m 19s
-
25m 1sPart 1 | Session 1 CHAMPION-AF: LAA Closure vs OAC in AF Outcomes
-
18m 33sPart 1 | Session 2 ALERT: Under-treatment in AS and MR
-
26m 37sPart 1 | Session 3 PRO-TAVI: TAVI With or Without Routine PCI
-
19m 43sPart 1 | Session 4 Dig-RHD: Digoxin in Rheumatic Heart Disease
-
6m 44sPart 2 | Session 1 VESALIUS-CV, KARDINAL, CHIP-BCIS3 & More
-
9m 4sPart 2 | Session 2 CHAMPION-AF, HI-PEITHO, STEMI-DTU
-
5m 51sPart 3 | Session 1 Door to Unload Randomized Clinical Trial
-
5m 58sPart 3 | Session 2 ALL-RISE – Coronary Physiology From Angiography vs Pressure Wire for PCI
-
6m 28s
-
8m 35sPart 3 | Session 4 The STEMI-DTU Trial – Primary Unloading and Delayed Reperfusion in STEMI
American College of Cardiology Congress 2026 – Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of tirzepatide compared with dulaglutide on expanded cardiorenal outcomes from the SURPASS-CVOT trial (NCT04255433; Eli Lilly and Company).
This international, double-blind, randomised, phase III cardiovascular outcomes trial enrolled 13,299 patients aged 40 and older with type 2 diabetes, established cardiovascular disease and HbA1c between 7% and 10.5%. Participants were randomised to subcutaneous tirzepatide or dulaglutide, administered once weekly, with follow-up extending up to 54 months. The primary endpoint was time to first occurrence of 3-point MACE comprising cardiovascular death, myocardial infarction or stroke. A comprehensive secondary programme was also implemented evaluating all-cause mortality, heart failure hospitalisation, renal outcomes, weight loss and lipid and glycaemic parameters.
Findings showed that in patients with diabetes and ASCVD, tirzepatide was associated with a lower incidence of a composite endpoint of all-cause mortality, myocardial infarction, stroke, coronary revascularization, heart failure and adverse renal outcomes.
Interview Questions:
- What was the rationale for this expanded cardiorenal outcomes analysis and what additional endpoints did it encompass beyond 3-point MACE?
- What were the key findings?
- How did the cardiorenal benefits align with the metabolic differences observed between the 2 agents — specifically weight reduction, HbA1c lowering and changes in urinary albumin-to-creatinine ratio?
- Based on the cardiorenal outcomes, how should clinicians prioritise tirzepatide relative to other GLP-1 receptor agonists and SGLT2 inhibitors in patients with type 2 diabetes and established cardiovascular or renal disease?
- What are your key take-home messages for clinicians and what are the next steps?
Recorded on-site at ACC 2026, New Orleans.
For more expert insights and late-breaking science from ACC 2026, visit the Late-breaking Science Video Collection.
Editor: Jordan Rance
Videographer:
Support: This is an independent interview produced by Radcliffe Cardiology.
Keep up-to-date with our video collection from the American College of Cardiology's 75th Annual Scientific Session, bringing you the latest from late-breaking science, featured research, and clinical horizon sessions.
Catch our congress preview and wrap-up in the NVM Cardiology Meeting Reflections series, alongside concise Expert Interviews with leading faculty distilling the key take-home messages for clinical practice — plus in-depth Highlights breaking down the most impactful trials of the meeting.
More from this programme
Part 1
Late-Breaker Discussions
Part 2
Between the Sessions with Dr Purvi Parwani
Part 3
Expert Interviews
Part 4
Highlights
Part 5
Market Watch
Part 6
NVM Cardiology Meeting Reflections
Faculty Biographies
Steven E Nissen
Cardiologist
Dr Steven E. Nissen, an esteemed American cardiologist, researcher, and patient advocate, has left an indelible mark in the field of cardiology. Formerly the chairman of cardiovascular medicine at the renowned Cleveland Clinic in Ohio, Dr Nissen brings a wealth of experience and expertise to his roles.
Joining the Cleveland Clinic in 1992, Dr. Nissen held key positions, including Vice-Chairman of the Department of Cardiology, Section Head of Clinical Cardiology, and Director of the Coronary Intensive Care Unit. In his most recent role, he served as the Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), overseeing multi-center clinical trials. Dr Nissen continues to contribute periodically in the Cardiac Critical Care Unit, showcasing his ongoing commitment to patient care.
A highly accomplished academic, Dr Nissen graduated from the Webb School of California before pursuing his undergraduate degree at the University of Michigan. He earned…
Comments